Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Wits University begins South African trial of Novavax COVID-19 vaccine

NVX-CoV2373 is produced by the biotech company, Novavax (Maryland, U.S.A). Novavax is a late-stage biotechnology company that develops next-generation vaccines for serious infectious diseases.

17 Aug 2020

FDA approves drug for treatment of neuromyelitis optica spectrum disorder

The U.S. Food and Drug Administration has approved Enspryng (satralizumab-mwge) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults with a particular antibody - patients who are anti-aquaporin-4 or AQP4 antibody-positive.

17 Aug 2020

Politics slows flow of US pandemic relief funds to public health agencies

As the coronavirus began to spread through Minneapolis this spring, Health Commissioner Gretchen Musicant tore up her budget to find funds to combat the crisis. Money for test kits.

17 Aug 2020

Cyborg technology: Researchers take new step toward integrating electronics with the body

Although true "cyborgs" - part human, part robotic beings - are science fiction, researchers are taking steps toward integrating electronics with the body.

17 Aug 2020

Back-pain patients taking opioid painkillers produce anti-opioid antibodies

University of Wisconsin-Madison scientists have discovered that a majority of back-pain patients they tested who were taking opioid painkillers produced anti-opioid antibodies.

17 Aug 2020

New test provides information on immune response to Sars-Cov-2 in transplant patients

Even patients with suppressed immune systems can achieve a strong immune response to Sars-Cov-2. A test helps to adapt therapy following an infection.

17 Aug 2020

Combination of nanotechnology and genetic engineering for regulating fatal cancer stemness

The development of chemotherapeutic agents with selective anti-cancer activities is increasingly unattractive due to the emergence of resistance, poor targeting of cancer tissues, and subsequent metastasis.

17 Aug 2020

Scientists claim signs of lasting SARS-CoV-2 immunity

Questions have been raised by many health experts on whether being infected with SARS-CoV-2 brings lasting immunity. Now, scientists have uncovered signs of strong and lasting immunity in people who even had a mild illness of COVID-19.

17 Aug 2020

Coronacept - A trap-and-destroy molecule against SARS-CoV-2

A new study published on the preprint server bioRxiv* in August 2020 reports a novel engineered molecule based on human and other mammalian orthologues of ACE2 fused with the Fc part of the antibody. This molecule interacts more tightly with the viral receptor-binding domain (RBD) to constitute a powerful immunoadhesin that targets the virus for destruction.

17 Aug 2020

Targeting SARS-CoV-2 with off-the-shelf CAR-NK cells

The current COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread and cause disease and death in many countries even today. At present, there is no effective treatment. A recent study published on the preprint server bioRxiv in August 2020 reports the potential of a new class of drugs called CAR NK cells, which could be used off-the-shelf to treat this disease.

17 Aug 2020

Frequently used serology test may not detect SARS-CoV-2 antibodies, shows study

Two different types of detectable antibody responses in SARS-CoV-2 (COVID-19) tell very different stories and may indicate ways to enhance public health efforts against the disease, according to researchers at The University of Texas MD Anderson Cancer Center.

15 Aug 2020

Influenza-virus-based vaccine platform another viable option against SARS-CoV-2

In a novel proof of concept study, published on the bioRxiv preprint server, U.S. researchers used attenuated influenza viral particles that express severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor-binding domain to induce neutralizing antibodies in mice – unveiling another viable vaccine candidate for preventing coronavirus disease (COVID-19).

14 Aug 2020

Preliminary Mayo Clinic results from convalescent plasma in 35,322 patients

A new study published on the preprint server bioRxiv* in August 2020 reports the preliminary results of the US Expanded Access Program (EAP) for CP. The EAP aimed to facilitate access to CP as well as to evaluate the safety of this therapy. However, the current study reports the results of an initial assessment of this agent.

14 Aug 2020

De novo designed SARS-CoV-2 nanoparticle vaccine

In light of the continuing threat to public health, social functioning, and economic activity posed by the COVID-19 pandemic, scientists are working urgently to bring out a vaccine that is both safe and effective, and capable of mass production. A new paper published on the preprint server bioRxiv* in August 2020 shows that such a vaccine may be produced by using arrays of one severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein on a nanoparticle platform.

14 Aug 2020

Experimental COVID-19 vaccine prevents severe disease in mice

Now, a novel experimental vaccine that is made from a mild virus genetically-modified to carry an essential gene from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronary disease (COVID-19), has shown promise in preventing pneumonia in mice infected with the virus.

14 Aug 2020

Natural controllers shed light on immunity mechanisms against hepatitis B

Infections in humans caused by the hepatitis B virus (HBV) represent a major public health problem. Despite the availability of effective protective vaccines, more than 250 million individuals worldwide are chronically infected according to WHO estimates.

13 Aug 2020

Synthetic nanobodies prevent SARS-CoV-2 infection

A team of researchers from the University of California San Francisco has created a powerful nasal spray or inhaler that can provide high-grade protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The report is presently available on the bioRvix* preprint server.

13 Aug 2020

Scientists identify genetic link to predict treatment response in patients with aggressive blood cancer

A Singapore team led by clinician-scientists and researchers from the National Cancer Centre Singapore (NCCS) discovered a genetic link to better predict treatment response for relapsed/refractory patients with natural- killer T-cell lymphoma (NKTCL), a highly aggressive form of blood cancer.

13 Aug 2020

Promega introduces new serological antibody test for COVID-19

Promega Corporation today announced the launch of its new serological antibody test for COVID-19 to detect the presence of antibodies against the SARS-CoV-2 virus.

From Promega Corporation 13 Aug 2020

Reelin inhibition may be effective for treating multiple sclerosis

In an animal model of multiple sclerosis (MS), decreasing the amount of a protein made in the liver significantly protected against development of the disease's characteristic symptoms and promoted recovery in symptomatic animals, UTSW scientists report.

12 Aug 2020